Poster Discussion. Jordan Berlin, M.D. Ingram Associate Professor, Medicine. Yes, I have a Consultant or Advisory Role to disclose. Amgen BMS Genentech Imclone Immunogen Pfizer Sanofi Yes, I have Honoraria to disclose. BMS Genentech Sanofi-Aventis. DSMB Pfizer
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Jordan Berlin, M.D.
Ingram Associate Professor, Medicine
Yes, I have Honoraria to disclose.
Took a pen
Genentech, but I promise I’ll give it backDisclosures
Adjuvant chemotherapy alone vs chemoradiation after curative resection for pancreatic cancer:Feasibility results of a randomized EORTC/FFCD/GERCOR phase II/III study (40013/22012/9203)
1JL. Van Laethem, 2E. Van Cutsem, 3P. Hammel, 4F. Mornex, 5D. Azria, 6G. Van Tienhoven, 7M. Peeters, 8M. Praet, 9V. Budach, 2K. Haustermans
1Hôpital Universitaire Erasme, Brussels (BE) - 2U.Z. Gasthuisberg, Leuven (BE) - 3Hôpital Beaujon, Clichy (FR) - 4CHU Lyon (FR) - 5CRLC Val d’Aurelle, Montpellier (FR) - 6AMC, Amsterdam (NL) - 7Universiteit Gent (BE) - 8EORTC, Brussels (BE) - 9Charite Berlin (DE)
Study design resection for pancreatic cancer:
Multicentre phase II/III study
Arm A (n = 45): Gemcitabine x 4 cycles (4 week cycles)
Within 8 weeks of
R0 Margin status
Arm B (n = 45):
Gemcitabine x 2 cycles then
gemcitabine + XRT
*Answer to the ultimate question according to the 5 books of the Douglas Adams classic Hitchiker’s Guide to the Galaxy trilogy
EORTC set out to answer the ultimate question
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301).
E. Mitry, L. Dahan, M. Ychou, J. Arthaud, M. Gasmi, J. Raoul, C. Mariette, J. M. Phelip, L. Bedenne, J.F. Seitz, Fédération Francophone de Cancérologie Digestive
Study design sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301).
Multicentre phase III study
To compare the best sequence of chemotherapy
Arm A: LV5FU2-P followed by Gemcitabine at progression or toxicity
Gemcitabine followed by LV5FU2-P at progression or toxicity
Gemcitabine: 1000 mg/m² on D1 as a 30 mn infusion or with an infusion rate of 10 mg/m2/min* , weekly 7 weeks /8, then 3 weeks / 4
LV5FU2-P: 2-hour infusion of LV 200 mg/m2 followed by a FU bolus 400 mg/m2 and 46-hour infusion 2,400 mg/m2 every 2 weeks, with cisplatin 50 mg/m2 as a 2-hour infusion on D1 or D2
(* Each participating centre had to always use the same administration method)
A PHASE 2 STUDY OF BEVACIZUMAB PLUS ERLOTINIB IN PATIENTS WITH GEMCITABINE-REFRACTORY METASTATIC PANCREATIC CANCER
AH Ko, E Dito, B Schillinger, AP Venook, EK Bergsland, WM Korn, MA Tempero
A Phase II Trial of Sunitinib (S) in Previously-Treated Pancreas Adenocarcinoma (PAC), CALGB 80603
E.M. O’Reilly, D. Niedzwiecki, D. Hollis, T. Bekaii-Saab, T. Pluard, A. Duffy, F. Overcash, P. Ivy, R.M. Goldberg
Long Term Outcome of Peptide Receptor Radionuclide Therapy in 441 Patients with Progressive Neuroendocrine Tumors Using Yttrium-90 and Lutetium-177 labelled Somatostatin Receptor Targeting Peptides
Dieter Hörsch, Vikas Prasad, Richard P. Baum
Department of Internal Medicine and Nuclear Medicine / Center for PET/CT Zentralklinik Bad Berka
Is this the future of
radiation for NE tumors?
Bad Berka Procedure for PRRT in 441 Patients with Progressive Neuroendocrine Tumors Using Yttrium-90 and Lutetium-177 labelled Somatostatin Receptor Targeting Peptides
Studies before therapy
90Y / 177Lu-DOTA-TATE Peptide Receptor Radiotherapy
Infusion of aminoacid solution (- 0.5 til 4 hrs)
Infusion (15 min.) of
90Y / 177Lu- DOTA-TATE
- 2 days
Studies under therapy
177Lu- DOTA-TATE WB scan
[planar scans for dosimetry]
177Lu- DOTA-TATE- SPECT
of the tumor region
* Since July 2004. Previously, Tc-99m EDDA Hynic TOC (planar & SPECT) was performed.
In selected patients, also F-18 FDG and / or F-18 fluoride PET/CT is performed as well as MRI of the liver / bones
Response to PRRT – Different Treatment Regimens in 441 Patients with Progressive Neuroendocrine Tumors Using Yttrium-90 and Lutetium-177 labelled Somatostatin Receptor Targeting Peptides
Highest response rate was observed with Y-90 followed by
Lu-177 + Y-90 and Lu-177 DOTA-TATEalone